Your browser doesn't support javascript.
loading
Involvement of kallikrein-PAR2-proinflammatory pathway in severe trastuzumab-induced cardiotoxicity.
Sasaki, Ritsuko; Kurebayashi, Nagomi; Eguchi, Hidetaka; Horimoto, Yoshiya; Shiga, Takahiro; Miyazaki, Sakiko; Kashiyama, Taku; Akamatsu, Wado; Saito, Mitsue.
Afiliação
  • Sasaki R; Department of Breast Oncology, Juntendo University Graduate School of Medicine, Tokyo, Japan.
  • Kurebayashi N; Department of Cellular and Molecular Pharmacology, Juntendo University Graduate School of Medicine, Tokyo, Japan.
  • Eguchi H; Intractable Disease Research Center, Juntendo University Graduate School of Medicine, Tokyo, Japan.
  • Horimoto Y; Department of Breast Oncology, Juntendo University Graduate School of Medicine, Tokyo, Japan.
  • Shiga T; Center for Genomic and Regenerative Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan.
  • Miyazaki S; Department of Cardiovascular Biology and Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan.
  • Kashiyama T; Department of Cellular and Molecular Pharmacology, Juntendo University Graduate School of Medicine, Tokyo, Japan.
  • Akamatsu W; Center for Genomic and Regenerative Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan.
  • Saito M; Department of Breast Oncology, Juntendo University Graduate School of Medicine, Tokyo, Japan.
Cancer Sci ; 113(10): 3449-3462, 2022 Oct.
Article em En | MEDLINE | ID: mdl-35879248
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Receptor PAR-2 / Cardiotoxicidade Tipo de estudo: Etiology_studies Limite: Humans Idioma: En Revista: Cancer Sci Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Japão
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Receptor PAR-2 / Cardiotoxicidade Tipo de estudo: Etiology_studies Limite: Humans Idioma: En Revista: Cancer Sci Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Japão